Lilly Acquires Diabetes Candidates In Deal With Transition Therapeutics
This article was originally published in The Pink Sheet Daily
After ending its efforts to develop inhaled insulin, Lilly rebuilds in-house pipeline of diabetes candidates.
You may also be interested in...
Disease charities are traditionally big funders of basic research. But those foundations are increasingly spawning specialized funds aimed at helping start-ups drive their candidates into later stages of development, where they might represent more attractive investment opportunities for pharmaceutical partners.
Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.
Third casualty in the space leaves one late-stage player standing.